What Is the EU Biocidal Products Regulation?

The EU Biocidal Products Regulation sets the rules for making biocidal products available on the EU market and using them safely. It applies to products intended to control harmful organisms through chemical or biological active substances.

Examples of products that may fall under BPR include:

• Surface disinfectants
• Hand disinfectants
• Industrial preservatives
• Wood preservatives
• Insecticides
• Rodenticides
• Repellents and attractants
• Antimicrobial coatings
• Treated textiles
• Treated plastics
• Filters, paints, packaging, or consumer goods with antimicrobial or preservative claims

ECHA states that all biocidal products must receive authorisation before they can be made available on the market, and companies may choose between different authorisation processes depending on their product and target countries.

This means that if your product has a biocidal function or makes a biocidal claim, you need to check whether BPR applies before selling it in the EU.

Does BPR Apply to Your Company?

BPR may apply to your business if you are:

• A manufacturer of biocidal products
• An importer placing biocidal products on the EU market
• A distributor selling biocidal products under your own brand
• A private-label company using third-party formulations
• A supplier of active substances
• A seller of treated articles
• A producer of materials treated with preservatives or antimicrobial substances
• A retailer or marketplace seller using claims such as “antibacterial,” “antimicrobial,” “mould-resistant,” “odour control,” or “disinfecting”
• A compliance, regulatory, quality, procurement, or product management team responsible for EU market access

Even if your company does not manufacture the active substance or formulation, you may still have BPR obligations if you import, sell, relabel, rebrand, or market the product in the EU.

Biocidal Product or Treated Article? A Key Client Question

One of the most common BPR questions is:

“Is my product a biocidal product or a treated article?”

This distinction matters because the compliance route, evidence, labelling, and authorisation requirements can be different.

It may be a biocidal product if:

The product’s main purpose is to control harmful organisms.

Examples include disinfectants, insecticides, repellents, rodenticides, preservatives, and products sold primarily for antimicrobial or pest-control purposes.

It may be a treated article if:

The product is not mainly sold as a biocide, but it has been treated with or intentionally incorporates a biocidal product.

Examples may include antimicrobial textiles, treated plastics, preserved paints, treated filters, odour-control materials, or mould-resistant consumer goods.

ECHA explains that treated articles can only be treated with biocidal products containing active substances approved in the EU. Suppliers must also provide consumers with information about the biocidal treatment free of charge within 45 days when requested.

Why this matters

If a company incorrectly classifies a product, it may:

• Sell without the required authorisation
• Use an unsupported active substance
• Miss treated article labelling obligations
• Make non-compliant antimicrobial claims
• Fail customer compliance checks
• Face delays, product withdrawal, relabelling, or enforcement risk

This is why a BPR applicability assessment is often the first step in a serious compliance programme.

Latest EU BPR Updates Companies Should Know in 2026

1. Certain BPR data protection periods have been extended until 31 December 2030

Regulation (EU) 2026/1165 amended the BPR as regards the extension of certain data protection periods. The regulation states that for affected active substance/product-type combinations, data protection periods are extended until 31 December 2030. It also explains that the review programme for existing biocidal active substances has been extended until the same date.

This update matters because BPR compliance often depends on costly data packages. Companies may need to check whether they have the right to rely on protected data, whether a Letter of Access is needed, and whether their supplier strategy remains valid.

2. IUCLID becomes mandatory for active substance renewal applications from 1 July 2026

From 1 July 2026, all applications to renew biocidal active substance approvals must contain approval data in IUCLID format. ECHA encourages companies to prepare their data in IUCLID and use the IUCLID Validation Assistant to support submissions.

ECHA also organised a 2026 webinar on preparing biocides active substance dossiers in IUCLID and R4BP 3, focusing on how to compile data correctly and avoid common obstacles before the deadline.

3. R4BP 3 and IUCLID dossier quality remain central to BPR submissions

ECHA’s biocides submission manuals are designed to help industry users build IUCLID dossiers and submit and manage BPR applications in R4BP 3 until a successful outcome is achieved.

4. BPR fees increased by 19.5% from 14 August 2025

ECHA announced that standard biocides fees increased by 19.5%, with updated fees applying from 14 August 2025. ECHA stated that SME fee reductions continue to apply under the existing rules.

5. ECHA introduced B-risk for biocides to support bee risk assessment

ECHA provides B-risk for biocides, a calculator designed to assess risks of biocides to bees and support consistency with guidance on bee risk assessment from biocidal uses.

6. Product assessment report templates have been updated

ECHA announced updated product assessment report templates for single biocidal products and biocidal product families. The updated templates are available for product authorisation applications submitted on or after 26 November 2025, while updated confidential annexes apply to applications submitted on or after 25 April 2027.

7. Union authorisations and active substance decisions continue to evolve

The EU continues to issue product family authorisations and active substance decisions. For example, Commission Implementing Regulation (EU) 2026/900 granted a Union authorisation for the Lactic Acid Product Family, valid from 17 May 2026 until 30 April 2036.

Key EU BPR Compliance Requirements

1. Product classification

You need to determine whether each product is:

• A biocidal product
• A biocidal product family
• A treated article
• Outside the scope of BPR

This decision should be based on formulation, function, intended use, claims, marketing language, active substances, and target organisms.

2. Active substance and product-type screening

Your company must check whether the active substance is approved, under review, or otherwise allowed for the relevant product type.

This check should include:

• Active substance identity
• CAS and EC numbers
• Product type
• Intended use
• Approval or review status
• Conditions of approval
• Supplier source
• Data access or Letter of Access status
• Technical equivalence considerations

3. Article 95 supplier validation

Article 95 is one of the most important BPR supplier-control obligations.

ECHA explains that the BPR uses Article 95 and the Article 95 list to establish a level playing field for parties dealing with active substances. ECHA also states that all biocidal products may only be made available on the market if either the substance supplier or product supplier is included on the Article 95 list.

For companies, this means supplier approval should not be based only on price, availability, or commercial relationship. It must include BPR supplier evidence.

A practical internal rule is:

No valid Article 95 evidence, no product release.

4. Authorisation route selection

Depending on the product and target markets, companies may need to choose between:

• National authorisation
• Mutual recognition
• Union authorisation
• Simplified authorisation
• Same biocidal product authorisation
• Biocidal product family authorisation

The right route depends on product type, active substances, intended use, number of target countries, commercial timeline, data ownership, and whether the product fits a product family strategy.

5. Label and advertising compliance

BPR compliance does not stop at authorisation.

Labels, websites, brochures, marketplace listings, safety information, technical datasheets, and sales claims must remain consistent with the authorised use and regulatory restrictions.

Common risk phrases include broad or unsupported claims such as:

• “Non-toxic”
• “Safe”
• “Harmless”
• “Chemical-free”
• “Kills all bacteria”
• “Antimicrobial protection” without clear evidence or scope
• “Disinfects” where the product is not authorised for that use

Marketing and regulatory teams should work from the same approved claims library.

6. Treated article compliance

For treated articles, companies need to know:

• Which components are treated
• Which active substances are used
• Why the treatment is applied
• Whether the active substance is approved for the relevant use
• Whether the product makes a biocidal claim
• Whether labelling is triggered
• Whether supplier declarations are complete
• Whether consumer information can be provided within 45 days when requested

This is especially important for textiles, plastics, furniture, filters, packaging, coatings, construction products, paints, and consumer goods with antimicrobial, odour-control, mould-resistant, or preservative claims.

7. Dossier readiness and documentation control

A BPR compliance file may need to include:

• Product identity
• Formulation and composition
• Active substance source
• Supplier declarations
• Article 95 evidence
• Product type assessment
• Efficacy data
• Human health risk assessment
• Environmental risk assessment
• Classification and labelling
• Summary of Product Characteristics
• Label and claims review
• Letters of Access
• R4BP 3 records
• IUCLID dossier information
• Renewal records
• Change-control history

If this information is scattered across emails, spreadsheets, PDFs, supplier portals, and local folders, BPR compliance becomes difficult to prove.

What Documents Should You Prepare Before a BPR Compliance Assessment?

A potential client usually wants to know what to prepare before starting.

For a BPR compliance review, your company should collect:

• Product list and SKU list
• Product labels
• Product claims and marketing text
• Safety Data Sheets
• Technical Data Sheets
• Formulation or composition information
• Active substance names and identifiers
• Supplier names and manufacturing sources
• Article 95 evidence
• Existing authorisation documents, if available
• Target EU countries
• Intended users, such as consumer, professional, or industrial users
• Product use instructions
• Treated article declarations
• Test reports or efficacy evidence
• Any existing Letters of Access
• Renewal deadlines or previous authority correspondence

This information helps determine whether the product is compliant, what gaps exist, and what action is needed before placing or keeping the product on the EU market.

What Happens If a Company Is Not BPR Compliant?

BPR non-compliance can create both regulatory and commercial risk.

Possible consequences include:

• Delayed EU market entry
• Product withdrawal
• Relabelling costs
• Rejected customer compliance requests
• Failed retailer or distributor onboarding
• Loss of supplier approval
• Dossier delays
• Extra testing or data costs
• Authority questions
• Enforcement risk
• Loss of trust with customers and business partners

For companies managing large product portfolios, the biggest risk is often not one missing document. It is the lack of a controlled system that shows which products are compliant, which are at risk, and which require action.

Common BPR Compliance Mistakes

Companies often run into BPR problems because compliance is managed manually or too late in the product launch process.

Common mistakes include:

• Assuming a product is outside BPR because it is not called a “biocide”
• Making antimicrobial claims without checking BPR scope
• Selling in multiple EU countries without checking the correct authorisation route
• Using an active substance approved for one product type but not another
• Forgetting Article 95 supplier validation
• Treating IUCLID and R4BP 3 as administrative steps instead of structured data requirements
• Not controlling labels and marketing claims after authorisation
• Missing treated article information obligations
• Failing to track renewal deadlines
• Not reassessing compliance after supplier, formulation, site, or claim changes

BPR Compliance Roadmap for Companies

A practical BPR compliance programme should follow these steps:

Step 1: Identify products in scope

Review your product portfolio, SKUs, treated materials, markets, and claims.

Step 2: Classify each product

Decide whether the product is a biocidal product, biocidal product family, treated article, or out of scope.

Step 3: Map active substances

Connect each product to its active substances, product type, supplier, and approval status.

Step 4: Validate Article 95 suppliers

Check whether the relevant substance or product supplier is listed and whether evidence is documented.

Step 5: Choose the authorisation route

Determine whether national authorisation, mutual recognition, Union authorisation, simplified authorisation, or product family authorisation is appropriate.

Step 6: Review labels and claims

Check whether product labels, websites, packaging, technical documents, and marketplace content match the allowed claims and uses.

Step 7: Build or review the dossier

Organise the technical documentation, supplier evidence, test data, risk assessments, authorisation documents, and submission records.

Step 8: Set up ongoing monitoring

Track regulatory updates, active substance decisions, renewal deadlines, supplier changes, formulation changes, and claim updates.

How ComplyMarket Product Compliance Software Helps with EU BPR Requirements

BPR compliance becomes easier when companies manage it as a structured workflow rather than a collection of disconnected documents.

ComplyMarket’s EU BPR compliance service describes support for product scoping, product type classification, biocide versus treated article determination, active substance and product-type screening, route recommendation, dossier preparation, label and advertising governance, treated article compliance, Article 95 supply-chain gating, renewal calendars, and inspection-ready records.

ComplyMarket’s broader product and material compliance platform also supports companies managing regulations, documentation, supplier compliance, and compliance data within the ComplyMarket portal.

What ComplyMarket can help you do

With ComplyMarket, companies can manage BPR compliance more efficiently by centralising:

• Product and SKU data
• Active substance information
• Product type classification
• Supplier evidence
• Article 95 documentation
• Treated article information
• Labels and claims
• Authorisation documents
• Dossier records
• Renewal deadlines
• Change-control history
• Audit-ready evidence

What You Get with ComplyMarket’s BPR Compliance Support

ComplyMarket helps companies move from uncertainty to a structured BPR compliance workflow.

1. BPR applicability assessment

ComplyMarket helps you identify which products, materials, components, SKUs, or treated articles may fall under BPR.

This helps answer the first client question:

“Does BPR apply to my product?”

2. Biocidal product vs treated article classification

ComplyMarket helps classify whether your product is a biocidal product, treated article, product family, or potentially outside BPR scope.

This helps answer:

“Do I need product authorisation, treated article controls, or both?”

3. Active substance and product-type screening

ComplyMarket helps map active substances against the relevant BPR product type and intended use.

This helps answer:

“Is my active substance allowed for this product and use?”

4. Article 95 supplier validation

ComplyMarket helps companies manage supplier evidence and Article 95 checks as part of the compliance workflow.

This helps answer:

“Can I legally use this supplier for EU market access?”

5. Dossier and evidence organisation

ComplyMarket helps structure supplier documents, labels, claims, active substance records, authorisation evidence, and renewal information in one place.

This helps answer:

“Can I prove compliance if a customer or authority asks?”

6. Label and claims governance

ComplyMarket supports controlled label and advertising workflows to reduce the risk of unsupported or non-compliant claims.

This helps answer:

“Are our labels, websites, and marketplace claims aligned with BPR?”

7. Treated article compliance management

ComplyMarket helps companies manage treated article evidence, supplier declarations, labelling triggers, and customer information obligations.

This helps answer:

“Can we prove what treatment was used and respond to information requests?”

8. Renewal and change-control tracking

ComplyMarket helps track renewal deadlines, regulatory changes, supplier changes, and product changes.

This helps answer:

“Will we know when something changes before it becomes a compliance problem?”

Why Companies Use Compliance Software for BPR

Manual BPR compliance can work for a small number of products, but it becomes risky when a company has:

• Many SKUs
• Multiple suppliers
• Several EU target markets
• Private-label products
• Treated articles
• Frequent supplier changes
• Multiple labels or languages
• Complex authorisation routes
• Customer compliance requests
• Audit obligations
• Renewal deadlines

Compliance software helps companies create one reliable source of truth.

Instead of asking, “Where is the latest supplier declaration?” or “Which products use this active substance?” teams can manage BPR evidence in a structured system linked to products, suppliers, substances, and markets.

EU BPR Compliance Checklist

Use this checklist to assess whether your company is ready.

Product scope

• Have you identified all products that may fall under BPR?
• Have you reviewed product claims, labels, and marketing language?
• Have you checked treated articles and treated components?

Classification

• Have you classified each product as a biocidal product, treated article, product family, or out of scope?
• Have you assigned the correct BPR product type?

Active substances

• Have you identified all active substances?
• Have you checked approval or review status?
• Have you checked product-type coverage?
• Have you reviewed approval conditions?

Supplier control

• Have you validated Article 95 supplier coverage?
• Have you collected supplier evidence?
• Do you track supplier or manufacturing-source changes?

Authorisation

• Have you selected the right authorisation route?
• Have you checked national, mutual recognition, Union, simplified, or product family options?
• Have you confirmed target EU countries?

Labels and claims

• Have you reviewed labels against authorised uses?
• Have you checked advertising claims?
• Have you controlled marketplace and distributor content?

Treated articles

• Do you know which articles are treated?
• Do you know which active substances are used?
• Can you provide consumer information within 45 days if requested?
• Have you checked labelling triggers?

Documentation

• Are your documents centralised?
• Are they version-controlled?
• Are renewal deadlines tracked?
• Are records inspection-ready?

If the answer to several of these questions is “no” or “not sure,” your company may need a BPR compliance review.

EU BPR Compliance FAQ

What is EU BPR compliance?

EU BPR compliance means ensuring that biocidal products and treated articles meet Regulation (EU) No 528/2012 requirements before and after they are placed on the EU market. This includes active substance checks, product authorisation, Article 95 supplier validation, treated article obligations, labelling, advertising, dossier management, renewals, and post-market compliance.

Do all biocidal products need authorisation?

Yes. ECHA states that all biocidal products must receive authorisation before they can be made available on the market.

What is Article 95 under BPR?

Article 95 relates to the list of relevant active substances and suppliers. ECHA explains that it helps establish a level playing field for parties dealing with active substances under BPR.

What is a treated article under BPR?

A treated article is an article treated with or intentionally incorporating a biocidal product. ECHA explains that treated articles may only be treated with biocidal products containing active substances approved in the EU, and suppliers must provide information about the treatment to consumers within 45 days when requested.

What changed for BPR in 2026?

Important 2026 updates include the extension of certain data protection periods until 31 December 2030 and the 1 July 2026 IUCLID requirement for active substance renewal applications.

Why use software for BPR compliance?

Software helps companies centralise product data, supplier evidence, active substance information, Article 95 records, labels, claims, treated article documentation, renewal deadlines, and audit evidence. This reduces manual work and helps teams prove compliance more efficiently.